Helen H. Wang

Helen H. Wang

Auto-generated profile, based on publicly available information

Helen H. Wang

Hagey Laboratory for Pediatric Regenerative Medicine, Division of Plastic and Reconstructive Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2004 in Wound Repair and Regeneration
Verified
Journal Article
Closed access
PDF file
MLMargaret M. Lotz
Margaret M. Lotz
HWHelen Wang
Helen Wang
JSJaekyung Cecilia Song
Jaekyung Cecilia Song
SPSusan E. Pories
Susan E. Pories
JMJeffrey B. Matthews
Jeffrey B. Matthews

27 September 2021 in Cell Reports Methods
Verified
Journal Article
Open access
CKChristian Kramme
Christian Kramme
APAlexandru M. Plesa
Alexandru M. Plesa
HWHelen H. Wang
Helen H. Wang
BWBennett Wolf
Bennett Wolf
MSMerrick Pierson Smela
Merrick Pierson Smela
GCGeorge M. Church
George M. Church
With the recent advancements in genome editing, next-generation sequencing (NGS), and scalable cloning techniques, scientists can now conduct genetic screens at unprecedented levels of scale and precision. With such a multitude of technologies, there is a need for a simple yet comprehensive pipeline to enable systematic mammalian genetic screening. In this study, we develop unique algorithms for target identification and a toxin-less Gateway cloning tool, termed MegaGate, for library cloning which, when combined with existing genetic perturbation methods and NGS-coupled readouts, enable versatile engineering of relevant mammalian cell lines. Our integrated pipeline for sequencing-based target ascertainment and modular perturbation screening (STAMPScreen) can thus be utilized for a host of cell state engineering applications.

7 November 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
HWHelen H. Wang
Helen H. Wang
MKMaria Korah
Maria Korah
SJSerena Jing
Serena Jing
CBCharlotte Elizabeth Berry
Charlotte Elizabeth Berry
MGMichelle Griffin
Michelle Griffin
MJMichael Januszyk
Michael Januszyk
Diabetes mellitus is an increasingly prevalent chronic metabolic disorder characterized by physiologic hyperglycemia that, when left uncontrolled, can lead to significant complications in multiple organs. Diabetic wounds are common in the general population, yet the underlying mechanism of impaired healing in such wounds remains unclear. Single-cell RNA-sequencing (scRNAseq) has recently emerged as a tool to study the gene expression of heterogeneous cell populations in skin wounds. Herein, we review the history of scRNAseq and its application to the study of diabetic wound healing, focusing on how innovations in single-cell sequencing have transformed strategies for fibroblast analysis. We summarize recent research on the role of fibroblasts in diabetic wound healing and describe the functional and cellular heterogeneity of skin fibroblasts. Moreover, we highlight future opportunities in diabetic wound fibroblast research, with a focus on characterizing distinct fibroblast subpopulations and their lineages. Leveraging single-cell technologies to explore fibroblast heterogeneity and the complex biology of diabetic wounds may reveal new therapeutic targets for improving wound healing and ultimately alleviate the clinical burden of chronic wounds.

22 October 2021 in STAR Protocols
Verified
Journal Article
Open access
CKChristian Kramme
Christian Kramme
APAlexandru M. Plesa
Alexandru M. Plesa
HWHelen H. Wang
Helen H. Wang
BWBennett Wolf
Bennett Wolf
MSMerrick Pierson Smela
Merrick Pierson Smela
GCGeorge M. Church
George M. Church
Gateway cloning employs the use of the ccdb toxin and has low colony numbers, making it difficult to apply at scale to clone libraries of cDNA vectors. In this protocol, we describe MegaGate, a toxin-less Gateway technology capable of robust cDNA library cloning that is efficient, cheap, and scalable. MegaGate eliminates the ccdb toxin used in Gateway recombinase cloning and instead utilizes meganuclease-mediated digestion to eliminate background vectors during cloning and is 99.8% efficient with high colony numbers.

18 November 2026 in Nature
Verified
Journal Article
Open access
MJMichael Januszyk
Michael Januszyk
JLJohn M. Lu
John M. Lu
MKMaria Korah
Maria Korah
SJSerena L. Jing
Serena L. Jing
PXPeter Y. Xie
Peter Y. Xie
Michael T. LongakerMichael T. Longaker
Michael T. Longaker
Current understanding of the host tissue response to solid tumours is largely based on investigations of tumour types in isolation1. Given the breadth and diversity of human tumour pathology and contributions of tumour microenvironment (TME) cells to disease progression, pan-cancer analysis is needed to bridge major themes of stromal and immune cell evolution. To date, however, efforts to compare the TME response across cancers have been limited in scope2,3. Here we conduct a comprehensive pan-cancer analysis by algorithmically screening thousands of publicly available single-cell transcriptomic datasets for stromal and immune signatures across species and tissue types. We demonstrate conserved hallmarks of host cell transcriptional programming in response to malignancy across 42 cancer types in more than 2,000 human and mouse tumour samples. These findings are codified as an interactive web atlas ( tmeatlas.stanford.edu ) and software package (scTME) that will serve as practical resources for the systematic interrogation of the TME in tumours.

14 October 2026 in Nature Aging
Verified
Journal Article
Closed access
PDF file
APAlexandru M. Plesa
Alexandru M. Plesa
SJSascha Jung
Sascha Jung
HWHelen H. Wang
Helen H. Wang
FOFawad Omar
Fawad Omar
MSMichael Shadpour
Michael Shadpour
GCGeorge Church
George Church